Eli Lilly and Company (BVMF:LILY34)

Brazil flag Brazil · Delayed Price · Currency is BRL
141.12
+3.02 (2.19%)
At close: Aug 1, 2025, 4:55 PM GMT-3
2.19%
Market Cap3.80T
Revenue (ttm)280.96B
Net Income (ttm)63.68B
Shares Outn/a
EPS (ttm)70.46
PE Ratio59.66
Forward PE29.94
Dividend0.73 (0.52%)
Ex-Dividend DateMay 15, 2025
Volume27,220
Average Volume22,492
Open138.46
Previous Close138.10
Day's Range137.29 - 141.67
52-Week Range132.28 - 181.98
Beta0.40
RSI44.77
Earnings DateAug 7, 2025

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals in the United States, Europe, China, Japan, and internationally. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Ja... [Read more]

Sector Healthcare
Founded 1876
Employees 47,000
Stock Exchange Brazil Stock Exchange
Ticker Symbol LILY34
Full Company Profile

Financial Performance

In 2024, Eli Lilly and Company's revenue was $45.04 billion, an increase of 32.00% compared to the previous year's $34.12 billion. Earnings were $10.59 billion, an increase of 102.08%.

Financial numbers in USD Financial Statements

News

There is no news available yet.